Osteoblast differentiation is regulated by Runx2, Sp7, and canonical Wnt signaling 1 . Since Runx2 is expressed in Sp7-deficient (Sp7 −/− ) mice and Ctnnb1 conditional knockout mice, Runx2 is the furthest upstream transcription factor in the regulation of osteoblast differentiation, and Runx2, Sp7, and canonical Wnt signaling are mutually regulated and maintain their expression 1,2 . Both osteoblast differentiation and the expansion of osteoblast progenitors are essential for bone development and bone regeneration. Although the mechanism for osteoblast differentiation has been well studied, the mechanism for the proliferation of osteoblast progenitors remains to be clarified 1 .
. FGF signals trigger a number of responses in target cells, including stemness, proliferation, anti-apoptosis, drug resistance, angiogenesis, epithelial-to-mesenchymal transition, and invasion, through RAS-MAPK, PI3K-AKT, PLCγ and DAG, and PLCγ and IP3. Furthermore, the FGF signaling pathway has crosstalk with the canonical Wnt signaling cascade. In cell proliferation, FGF signaling plays important roles through RAS-MAPK, PI3K-AKT, and canonical Wnt signaling 20, 21 . Genomic alterations in FGFRs are associated with various cancers, including breast cancer, lung cancer, gastric cancer, multiple myeloma, myeloproliferative syndrome, rhabdomyosarcoma, peripheral T-cell lymphoma, uterine tumors, and bladder tumors 20, 21 . We previously reported that Runx2 transgenic mice under the control of the Prrx1 promoter, which directs transgene expression to the limb bud mesenchyme and cranial mesenchyme from embryonic day (E) 9.5 22 , exhibit craniosynostosis, ectopic bone formation, and limb defects 23 . Since FGF signaling plays an important role in limb development, we examined the involvement of Runx2 in the FGF signaling pathway in this study. Runx2 directly regulated the Fgfr1, Fgfr2, and Fgfr3 genes. In order to elucidate the physiological role of Runx2 in the regulation of Fgfr1-3 expression, we further examined the proliferation of osteoblast progenitors. We found that Runx2 was required for the proliferation of osteoblast progenitors, and also that it induced proliferation, at least in part, through the regulation of Fgfr2 and Fgfr3.
Results
Defects in Fgf signaling for limb development in Tg(Prrx1-Runx2) mice. We previously reported that the early onset of Runx2 expression causes craniosynostosis, ectopic bone formation, and limb defects, and also that the severity of limb defects depends on the expression levels of the transgene 23 . An epithelial-mesenchymal interaction loop formed by Fgfs and Fgfrs is essential for limb development. Fgf10, which first appears in the mesenchyme, has affinity for Fgfr2b in the apical ectodermal ridge (AER), which is a thickening of the ectoderm at the apex of the developing limb bud and is formed along the border of dorsal and ventral ectoderm, and induces Fgf8 and Fgf4 in the AER. Fgf8 and Fgf4 have affinity for Fgfr1c and Fgfr2c expressed in the mesenchyme, and promote mesenchymal proliferation and the outgrowth of limb buds 10, [24] [25] [26] [27] [28] [29] [30] [31] [32] . The Fgf8 and Fgf4, which are expressed in AER, and Shh, which is expressed in the zone of polarizing activity (ZPA), mutually support the expression [33] [34] [35] . In order to elucidate the mechanisms responsible for limb defects, we examined the expression of Fgf10 at E10.0 and that of Fgf8, Fgf4, and Shh at E10.5 in Tg(Prrx1-EGFP-Runx2) mice with high expression levels using whole mount in situ hybridization (Fig. 1A-H ). Since Tg(Prrx1-EGFP-Runx2) mice were lethal at birth, we analyzed F 0 littermates of wild-type and Tg(Prrx1-EGFP-Runx2) mice in each whole mount in situ hybridization. Therefore, the severity of the defect in limb development was different among F 0 Tg(Prrx1-EGFP-Runx2) mice depending on the expression level of the transgene as previously described 23 . Fgf10 mRNA was detected in wildtype and Tg(Prrx1-EGFP-Runx2) mice, while Fgf8, Fgf4, and Shh mRNA was detected in wild-type mice, but not in Tg(Prrx1-EGFP-Runx2) mice. In histological analyses, the AER was observed in the limb buds of wild-type mice, but was not apparent in Tg(Prrx1-EGFP-Runx2) mice at E10.5 ( Fig. 1I,J) . The endogenous Runx2 protein was undetectable in wild-type mice, while the Runx2 protein was present in mesenchymal cells, but not in the epithelium of the limb buds of Tg(Prrx1-EGFP-Runx2) mice (Fig. 1K,L) . Fgf8 mRNA was detected in the AER of the limb buds of wild-type mice, but not in Tg(Prrx1-EGFP-Runx2) mice (Fig. 1M,N) , and the number of TUNEL-positive cells was higher in the presumptive AER region of Tg(Prrx1-EGFP-Runx2) mice than in the AER of the limbs of wild-type mice ( Fig. 1O,P) . Enhanced apoptosis in the AER region was also observed in Fgf4 and Fgf8 double mutant mice 32 . Therefore, these results suggest that FGF10, which was expressed in mesenchymal cells, failed to induce Fgf8 and Fgf4 mRNA expression in the ectoderm, leading to the apoptosis of cells in the AER region of Tg(Prrx1-EGFP -Runx2) mice with high expression levels. Thus, ectopic expression of Runx2 in limb bud mesenchyme disturbed the induction of Fgf8 and Fgf4 expression in ectoderm by Fgf10 produced in mesenchyme.
Runx2 regulates the expression of Fgfr1, Fgfr2, and Fgfr3. Since Fgf10 mRNA was detected in mesenchymal cells, whereas Fgf8 and Fgf4 mRNA was not observed in the epithelium in Tg(Prrx1-EGFP-Runx2) mice, the expression of Fgfrs or their isoforms might have been disturbed in Tg(Prrx1-EGFP-Runx2) mice. Therefore, we examined the expression of Fgfr1-3 and their isoforms by real-time RT-PCR using RNA from EGFP-positive cells sorted from the cell suspensions of Tg(Prrx1-EGFP) mice and Tg(Prrx1-EGFP-Runx2) mice at E10.5 (Fig. 2) . Fgfr1b, Fgfr1c, Fgfr2c, Fgfr3b, and Fgfr3c mRNA levels were significantly higher in Tg(Prrx1-EGFP-Runx2) mice than in Tg(Prrx1-EGFP) mice. The Runx2 expression in Tg(Prrx1-EGFP-Runx2) mice was 16 times higher than that in Tg(Prrx1-EGFP) mice in the microarray analysis using the sorted EGFP-positive cells (data not shown). Since Runx2 expression was not detected in wild-type limb buds (Fig. 1K) , SCieNTifiC RepoRts | (2018) 8:13551 | DOI:10.1038/s41598-018-31853-0 the regulation of Fgfrs at this developmental stage is not a physiological function of Runx2. Therefore, we examined whether Runx2 induces the expression of Fgfr1-3 in osteoblast progenitors prepared from wild-type calvarial cells as described in the Materials and methods (Fig. 3A) . Infection with type II Runx2-expressing adenovirus induced Fgfr1, Fgfr2, and Fgfr3 mRNA and their IIIb and IIIc isoform mRNA. Since the induction of Fgfr2 by Runx2 in osteoblast progenitors was more apparent than that in limb bud mesenchymal cells at E10.5 (Figs 2 and 3A), it is likely that the transcription factors and/or co-factors collaborating with Runx2 for Fgfr2 expression is more abundant in osteoblast progenitors than limb bud mesenchymal cells at E10.5. Further, the expression of the molecules related to alternative splicing may be also different, because Fgfr2b expression was not significantly upregulated in limb bud mesenchymal cells at E10.5 (Fig. 2) . The induction of Fgfr1, Fgfr2, Fgfr3, and Fgfr4 mRNA by Runx2 has also been reported by microarray analysis using RNA from immortalized Runx2 −/− calvarial cells infected with Runx2-expressing adenovirus 36 . The introduction of Runx2 siRNA in osteoblast progenitors reduced the expression of Fgfr2 and Fgfr3 (Fig. 3B) . However, Runx2 siRNA reduced Runx3 mRNA as well as Runx2 mRNA, although the siRNA sequence was specific for Runx2. Therefore, we examined whether Runx2 regulates Runx3 expression (Supplemental Fig. 1 ). Runx3, but not Runx1 expression was markedly weaker in Runx2 −/− calvariae than in wild-type and Sp7 −/− calvariae (Supplemental Fig. 1A ). The overexpression of Runx2 induced the expression of Runx3, but not that of Runx1 in wild-type osteoblast progenitors (Supplemental Fig. 1B ). The overexpression of Runx3 induced neither Runx1 nor Runx2. Furthermore, the overexpression of Runx3 failed to induce Fgfr1, Fgfr2, and Fgfr3 (Supplemental Fig. 1B ). These results indicated that Runx2, but not Runx3 regulates Fgfr1, Fgfr2, and Fgfr3. (Fig. 4) . In the reporter assay using a 10-kb fragment of the Fgfr1 promoter region, which contains eighteen consensus Runx2-binding motifs (TGPyGGPy), Runx2 strongly induced reporter activity (Fig. 4A) . Serial deletions of the 10-kb fragment showed that the distal 4 kb is, in part, responsible for Runx2-dependent transcriptional activation; however, further deletions augmented Runx2-dependent transcriptional activation, and Runx2 still activated the reporter activity of the 0.2-kb fragment. In the 0.2-kb fragment, there was one overlapping Ets1-binding site and two putative Runx-binding sites, which contained the core four nucleotides of the consensus Runx2-binding motifs, R1 and R2 (Fig. 4B) . The mutation of R1, but not R2 completely abolished Runx2-dependent transcriptional activation (Fig. 4C) . Since R1 and the Ets1-binding sites are closely located, Runx2 and Ets1 may co-operatively bind to and activate the Fgfr1 promoter, as previously described for the Spp1 promoter 37 . It was not possible to confirm this because the mutation of the Ets1-binding site completely abolished the basal activity of the promoter (Fig. 4C) .
In the reporter assay using a 2.5-kb fragment of the Fgfr2 promoter region, which contains four consensus Runx2-binding sites, Runx2 induced reporter activity (Fig. 4D ). Serial deletions of the 2.5-kb fragment showed that the distal 1.13 kb was, in part, responsible for Runx2-dependent transcriptional activation; however, Runx2 maintained the ability to enhance the transcription of the reporter vector containing a 0.39-kb deletion fragment (Fig. 4D) . The 0.39-kb fragment contained one consensus Runx2-binding motif (R2) and three putative Runx2-binding sites consisting of the four core nucleotides of the consensus Runx2-binding sequences (R1, R3, R4) (Fig. 4E) . The mutation of R3 abolished Runx2-dependent transcriptional activation (Fig. 4F) .
In the reporter assay using an 8-kb fragment of the Fgfr3 promoter region, which contained fourteen consensus Runx2-binding motifs, Runx2 strongly induced reporter activity (Fig. 4G ). Serial deletions of the 8-kb fragment to the 2.6-kb fragment reduced Runx2-dependent transcriptional activation; however, further deletions to the 0.23-kb fragment augmented Runx2-dependent transcriptional activation. Thus, we focused on the 0.23-kb fragment, which contained two putative Runx2-binding sites, R1 and R2 (Fig. 4H ). The mutation of either R1 or R2 partly reduced Runx2-dependent transcriptional activation, and the mutations of both R1 and R2 completely abolished Runx2-dependent transcriptional activation (Fig. 4I) .
We then examined the binding of endogenous Runx2 in the promoter regions of Fgfr1, Fgfr2, and Fgfr3 by ChIP assays (Fig. 4J) . The promoter regions of Fgfr1 (−88 ~+199), Fgfr2 (−83 ~+216), and Fgfr3 (−188 ~+178), which contained the putative Runx2-binding sites responsible for Runx2-dependent transcriptional activation, were amplified by PCR using DNA immunoprecipitated with the anti-Runx2 antibody, but not with IgG.
Accumulation of proliferating osteoblast progenitors, which express Runx2 and Fgfr2, in calvariae and mandibles in Sp7 −/− mice, but not in Runx2 −/− mice. Although Runx2 is expressed in mesenchymal cells in the maxilla, mandible, and perichondrium of the humerus in Sp7 −/− mice, their differentiation into osteoblasts is completely blocked 38 . Since Runx2 regulated Fgfrs in osteoblast progenitors (Figs 3 and 4) , we focused on mesenchymal cells in intramembranous bone regions, including calvariae and mandibles, in Sp7 −/− mice in order to clarify the physiological roles of Fgfr gene regulation by Runx2. We compared the intramembranous bone area including the calvariae and mandibles in wild-type, Sp7 −/− , and Runx2 −/− mice at E18.5 (Fig. 5) . In wild-type mice, bone structures were established and osteoblasts strongly expressed Col1a1 (Fig. 5G ,J,M,P). Although Sp7 −/− mice and Runx2 −/− mice both showed no bone structure, the layer of mesenchymal cells in the calvarial region in Sp7 −/− mice was much thicker than that in Runx2 −/− mice ( Fig. 5G-I 
,S). The expression of Col1a1 in mesenchymal cells was weak in Sp7
−/− mice and Runx2 −/− mice, but stronger in Sp7 −/− mice than in Runx2 −/− mice, and the Col1a1-positive area in Sp7 −/− mandibles was much larger than that in Runx2
. Therefore, mesenchymal cells, which are considered to be osteoblast progenitors, were accumulated in calvariae and mandibles of Sp7 −/− mice but not of Runx2 −/− mice. In limb bone development in wild-type mice at E18.5, chondrocytes in epiphysis expressed Col2a1, and metaphysis and diaphysis were already replaced with bone and occupied by osteoblasts, which expressed Col1a1 (Supplemental Fig. 2A,D 
,G,J,M,P). Sp7
−/− mice completely lacked bone formation, and the limb skeletons were cartilaginous at E18.5 (Supplemental Fig. 2B ,E), as previously described 38 . Chondrocytes were maturated in the diaphysis, in which Col2a1 expression was absent, in Sp7 −/− mice (Supplemental Fig. 2H ,K). Osteoblast progenitors, which expressed Col1a1, were accumulated in the perichondrium of Sp7 −/− mice and some of them differentiated into morphologically chondrogenic cells, which expressed both Col2a1 and Col1a1 (Supplemental Fig. 2H ,K,N,Q). Although the limb skeletons were also cartilaginous in Runx2 −/− mice at E18.5, chondrocyte maturation was inhibited and chondrocytes in the entire femurs expressed Col2a1 (Supplemental Fig. 2C ,F,I,L), as previously described 39, 40 . The accumulation of mesenchymal cells in the perichondrium was absent, and osteoblast progenitors, which expressed Col1a1, were few (Supplemental Fig. 2O ,R). These findings indicate that Runx2 is required for the expansion of osteoblast progenitors in the perichondrium of endochondral bones.
We then performed immunohistochemistry using the anti-Runx2 and anti-Fgfr2 antibodies to examine the expression of Runx2 and Fgfr2 in osteoblast progenitors in Sp7 −/− mice. Runx2 and Fgfr2 were strongly detected in osteoblasts in wild-type mice and osteoblast progenitors in Sp7 −/− mice, but undetectable in the mesenchymal cells in Runx2 −/− mice, although Fgfr2 was detected in chondrocytes of Runx2 −/− mice ( Fig. 6A -I, M-R). Real-time RT-PCR and Western blot analyses showed that total Runx2 mRNA, type II Runx2 mRNA, and Runx2 protein are expressed at similar levels in wild-type and Sp7 −/− mice, that type I Runx2 mRNA is expressed at slightly higher levels in Sp7 −/− mice than wild-type mice, and that Sp7 mRNA levels are extremely low in Runx2 −/− mice ( Fig. 6V-X ). BrdU-positive osteoblasts or osteoblast progenitors were observed at similar frequencies in wild-type and Sp7 −/− mice, whereas BrdU-positive cells were severely reduced in mesenchymal cells in the calvarial region and mandible of Runx2 −/− mice (Fig. 6J -L,S-U,Y,Z). These results indicate that Runx2 is required for the proliferation of osteoblast progenitors and the expansion of osteoblast progenitors in Sp7 −/− mice.
Runx2 enhances the proliferation of osteoblast progenitors through Fgf signaling pathway. In order to investigate the functions of Fgfr1-3 in the proliferation of osteoblast progenitors, siRNA for Fgfr1, Fgfr2, or Fgfr3 was introduced by electroporation into wild-type osteoblast progenitors and cells were stimulated with FGF2 (Fig. 7A,B) . siRNA for Fgfr1 augmented FGF2-induced proliferation, while siRNAs for Fgfr2 and Fgfr3 inhibited FGF2-induced proliferation. The FGF2 treatment or the transfection of Runx2-expression vector by electroporation increased the proliferation of wild-type osteoblast progenitors, and the transfection of Runx2-expression vector enhanced FGF2-induced proliferation. The treatment with AZD4547, which is a specific Fgfr tyrosine kinase inhibitor that inhibits Fgfr1-3, reduced the proliferation of wild-type osteoblast progenitors and abrogated increases by FGF2 and/or Runx2 (Fig. 7C) . The MAPK inhibitor, U0126, exerted similar effects to AZD4547, whereas the PI3K inhibitor, LY294002, and Akt inhibitor failed to inhibit proliferation and FGF2-induced proliferation of wild-type osteoblast progenitors (Fig. 7D ). In accordance with these results, the treatment with FGF2 enhanced the phosphorylation of MAPK, and this phosphorylation was strongly inhibited by U0126 and AZD, whereas the treatment with FGF2 failed to enhance the phosphorylation of Akt (Fig. 7E,F) . These results indicate that Fgfr signaling through Fgfr2 and Fgfr3 regulates the proliferation of osteoblast progenitors mainly through the MAPK pathway, and that Runx2 enhances proliferation and FGF2-induced proliferation through the regulation of the Fgfr signaling pathway. −/− calvaria was faster than wild-type osteoblast progenitors, enhanced proliferation by FGF2 was markedly stronger in Sp7 −/− osteoblast progenitors than in wild-type osteoblast progenitors, and the treatment with AZD4547 abolished accelerated proliferation and enhanced FGF2-induced proliferation (Fig. 7G) . The introduction of siRNA for Runx2 into Sp7 −/− osteoblast progenitors reduced the expression of Ccnd1, Fgfr2, and Fgfr3 (Fig. 7H) as well as FGF2-induced proliferation (Fig. 7I) .
We compared the expression of Fgfr1-3 in the calvariae of wild-type, Sp7
, and Runx2 −/− mice using a droplet digital RT-PCR analysis, which detects the absolute number of each mRNA. The expression levels of Fgfr1-3 were Fgfr1 > Fgfr2 > Fgfr3 in wild-type and Runx2 −/− calvariae, and Fgfr1 = Fgfr2 > Fgfr3 in Sp7 −/− calvariae (Fig. 8A) . The expression of Fgfr4 was undetectable in wild-type calvariae (data not shown). Fgfr1, Fgfr2, and Fgfr3 mRNA levels were markedly lower in Runx2 −/− calvariae than in wild-type and Sp7 −/− calvariae. Although the level of Fgfr1 was lower in Sp7 −/− calvariae than in wild-type calvariae, those of Fgfr2 and Fgfr3 were similar between wild-type and Sp7 −/− calvariae (Fig. 8A ). In the ChIP assay using Sp7 −/− calvariae, Runx2-binding regions in Fgfr1, Fgfr2, and Fgfr3 were amplified by PCR in DNA precipitated with the anti-Runx2 antibody, but not with IgG (Fig. 8B) . These results indicate that Runx2 also directly regulates the expression of Fgfr2 and Fgfr3 in Sp7 −/− calvariae and enhances the FGF2-induced proliferation of Sp7 −/− osteoblast progenitors. We also examined whether FGFs enhances the Runx2 capacity for transcriptional activation. Either FGF2 or FGF18 enhanced Runx2-dependent transcription in the reporter assays using the luciferase vector containing six tandem repeats of a Runx2 binding site (6XOSE2) (Supplemental Fig. 3 ).
Signaling pathways involved in the proliferation of osteoblast progenitors. To investigate other signaling pathways than Fgf involved in the proliferation of osteoblast progenitors, the expression of cell proliferation-related genes in calvarial tissues of Sp7
−/− mice and Runx2 −/− mice was compared by microarray (Supplemental Tables 1 and 2 ). The expression of the genes in Wnt (Wnt10b, Lef1), hedgehog (Ihh), and Phtlh (Pth1r, Pthlh) signaling pathways was increased more than two times in Sp7 −/− calvarial tissues compared with Runx2 −/− calvarial tissues. Therefore, the effects of FGF2, Wnt3a, Ihh, Shh, and PTHrP (1-34) on the proliferation of wild-type osteoblast progenitors, which were transfected with either GFP-or Runx2-expression vector, were compared. Runx2 induced proliferation, and FGF2 but not Wnt3a, Ihh, Shh, and PTHrP (1-34) increased the proliferation in either GFP-or Runx2-transfected cells (Fig. 8C ).
Differential expression of the genes related to cell proliferation in Runx2
−/− osteoblast progenitors in vitro and in vivo. The proliferation of Runx2 −/− osteoblast progenitors was increased in vitro as previously described (Fig. 8D ) 6 . To clarify the reason for the discrepancy of the proliferation capacity of Runx2 −/− osteoblast progenitors in vitro and in vivo, the expression of the cell proliferation-related genes in Runx2 −/− osteoblast progenitors was compared with that in wild-type osteoblast progenitors in vitro, and that in Runx2 −/− calvarial tissues was compared with that in wild-type calvarial tissues by cap analysis of gene expression (CAGE). And the genes, in which the expression ratios in vitro were more than two times or less than half compared with the expression ratios in vivo, were selected (Supplemental Tables 3 and 4 ). Many genes related to cell proliferation were differentially expressed in Runx2 −/− osteoblast progenitors in vitro and in vivo. Further, the expression of Myc, Ccnd1, many growth factor genes, including Ereg, Hbegf, Tgfb1, Vegfa, Fgf7, Csf1, Fgf2, and Pdgfc, and a growth factor receptor gene Pth1r was upregulated in Runx2 −/− osteoblast progenitors in vitro than in vivo. The differential expression of many cell proliferation-related genes in vitro and in vivo may explain why Runx2 −/− osteoblast progenitors acquired augmented capacity for proliferation in vitro.
The proliferation of osteoblast progenitors in Sp7 −/− mice is dependent on the gene dosage of Runx2. In order to investigate whether the proliferation of osteoblast progenitors in Sp7 −/− mice is dependent on Runx2, we generated Sp7 −/− Runx2 +/− mice and compared them with Sp7 −/− Runx2 +/+ mice (Fig. 9 ). The width of the layer of osteoblast progenitors in calvariae in Sp7 −/− Runx2 +/− mice was about half of that in Sp7 −/− Runx2 +/+ mice, and the number of BrdU-positive osteoblast progenitors in calvariae was markedly lower in Sp7
Runx2
+/− mice than in Sp7 (Fig. 9K,L) . The number of BrdU-positive osteoblast progenitors in the mandible was also lower in Sp7
+/-mice than in Sp7 −/− Runx2 +/+ mice, but not by as much as that in calvariae (Fig. 9L,M) . Interestingly, the tibiae and fibulae in Sp7 −/− Runx2 +/+ mice were severely bent due to the accumulation of osteoblast progenitors, whereas those in Sp7
+/-mice were not bent due to the reduction in the amount of osteoblast progenitors compared with Sp7 −/− Runx2 +/+ mice (Supplemental Fig. 4 ). These results indicate that the proliferation of osteoblast progenitors in Sp7 −/− mice is dependent on the gene dosage of Runx2, and that the proliferation of osteoblast progenitors in calvariae is more dependent on the gene dosage of Runx2 than that in mandibles. mice were set as 1, and relative levels are shown. Data are the mean ± SE of 4-5 mice. *vs. wild-type mice. 
Discussion
Although Runx2 −/− mice and Sp7 −/− mice both completely lack osteoblasts and bone formation, osteoblast progenitors, which abundantly expressed Runx2, accumulated and actively proliferated in the calvaria and mandible of Sp7 −/− mice, and the number of osteoblast progenitors and their proliferation were dependent on the gene dosage of Runx2. Runx2 directly regulated Fgfr1-3 expression, enhanced the proliferation of osteoblast progenitors, and augmented the FGF2-induced proliferation through the Fgfr2/3-MAPK signaling pathway. Further, FGF2 but not Wnt3a, Ihh, Shh, and PTHrP (1-34) increased the proliferation and augmented Runx2-induced proliferation. These results indicate that Runx2 is a requisite transcription factor not only for osteoblast differentiation but also for proliferation of osteoblast progenitors, and that Runx2 regulates the proliferation of osteoblast progenitors, at least partly, through the induction of Fgfr2 and Fgfr3 expression. Since FGF10 binds with high affinity to Fgfr1b and Fgfr2b 41 , limb defects were likely to have been caused by the up-regulated expression of Fgfr1b in the mesenchyme of the limb buds of Tg(Prrx1-EGFP-Runx2) mice (Figs 1 and 2 ), which will interrupt the translocation of Fgf10 to the ectoderm leading to the failure of the induction of Fgf8 and Fgf4 expression in the ectoderm. Limb defects in Pfeiffer and Apert syndromes are similar to those in Tg(Prrx1-EGFP-Runx2) mice with low expression levels 17, 23, 42 . FGF2 phosphorylates Runx2 through the MAPK pathway and enhances the transcriptional activity of Runx2, ERK-dependent phosphorylation stabilizes the Runx2 protein, and Runx2 is activated through the PI3K-Akt pathway [43] [44] [45] [46] . We also confirmed that Runx2 capacity for the transcriptional activation is enhanced by FGF2 and FGF18 (Supplemental Fig. 3 ). Since Runx2 directly regulated the expression of Fgfr1-3, a positive feedback loop between FGFR signaling and RUNX2 may play an important role in the pathogenesis of craniosynostosis and limb defects caused by gain-of-function mutations in FGFR1-3. Runx2 −/− calvaria-derived osteoblast progenitors proliferated faster than wild-type osteoblast progenitors in vitro (Fig. 8D) , as previously reported 6 . However, the number of osteoblast progenitors in calvariae and mandibles of Runx2 −/− mice was quite low, and the BrdU + cells were severely reduced (Figs 5 and 6), indicating that there is a discrepancy in the proliferation of Runx2 −/− osteoblast progenitors in vitro and in vivo. It was previously 
−/− osteoblast progenitors in vitro, and the introduction of Runx2 induces the expression of Cdkn1b (p27 KIP1 ), Cdkn1a, and Cdkn2a, which prevent cell cycle progression through the inhibition of cyclin-dependent kinases (CDKs) or the stabilization of p53 by inhibiting Mdm2 7, 47 . The report also showed that severe reduction of Cdkn1a and Cdkn2a expression in Runx2 −/− osteoblast progenitors occurs after six passages of the cells 47 . We examined the proliferation and gene expression of Runx2 −/− osteoblast progenitors after one passage of the cells, trying to mimic in vivo situation. Cdkn1b expression in Runx2 −/− osteoblast progenitors was greater than that in wild-type osteoblast progenitors, Cdkn1a, Cdkn2a (p19 ARF ), and Cdkn2a (p16 Ink4a ) expression in Runx2 −/− osteoblast progenitors was about 75% of wild-type osteoblast progenitors, and the introduction of Runx2 failed to induce their expression in vitro (Supplemental Table 5 ). Further, their expression ratios in Runx2 −/− and wild-type osteoblast progenitors in vitro were much higher than those in Runx2 −/− and wild-type calvarial tissues in vivo (Supplemental Table 5 ), indicating that the enhanced proliferation of Runx2 −/− osteoblast progenitors in vitro cannot be explained by the expression levels of the CDK inhibitors. Since many genes related to cell proliferation were differentially expressed in Runx2 −/− osteoblast progenitors in vitro and in vivo (Supplemental Table 3 and 4), it seemed to be difficult to reveal the function of Runx2 in the proliferation of osteoblast progenitors by investigating Runx2
Reductions in the volume of osteoblast progenitors and their frequencies in BrdU uptake in the calvariae were greater than those in the mandibles in Sp7 −/− Runx2 +/-mice relative to the respective tissues in Sp7 −/− Runx2 +/+ mice ( Fig. 9) , indicating that osteoblast progenitor proliferation is more dependent on the gene dosage of Runx2 in calvariae than mandibles. It may partly explain why open fontanelles and sutures are prominent phenotypes in cleidocranial dysplasia, which is caused by heterozygous mutation of RUNX2 48 . High dependency on the amount of Runx2 protein among Runx family transcription factors in calvarial bone development is also shown in the comparison of Runx2 +/-mice with conditional Cbfb knockout mice or Cbfb isoform knockout mice 49, 50 . As osteoblast progenitors were scarce and the BrdU-positive cells were few in both regions of calvaria and mandible in Runx2 −/− mice (Figs 5 and 6), however, our findings also indicate that Runx2 is required for the proliferation of osteoblast progenitors in both calvaria and mandible. During endochondral bone development, osteoblast differentiation occurs first in the perichondrium, and Sp7-expressing preosteoblasts invade the cartilage with blood vessels and give rise to trabecular osteoblasts 51 . The accumulation of osteoblast progenitors was observed in the perichondrium of cartilaginous limb skeletons of Sp7 −/− mice but not in Runx2 −/− mice, and the accumulation of osteoblast progenitors in Sp7 −/− limb skeletons was also dependent on the gene dosage of Runx2 (Supplemental Figs 2 and 4), indicating that Runx2 is also required for the proliferation of osteoblast progenitors for trabecular osteoblasts.
Runx2 is required for mammary gland development, and Runx2 deletion increased animal survival in a mouse model of breast cancer with reduced proliferation and cyclin D expression 52 . The strong expression of Runx2 is associated with estrogen receptor/progesterone receptor/HER2-negative breast cancer and patients with strong Runx2 expression have a poorer survival rate than those with negative or weak expression 53 . The FGFR2 gene has been identified as a locus associated with an increased risk of developing breast cancer, and a single nucleotide polymorphism in the FGFR2 gene, which enhances RUNX2 binding, increases FGFR2 expression [54] [55] [56] [57] . Furthermore, the knockdown of RUNX2 reduced the expression of FGFR2 in the breast cancer cell line MCT-7 58 . Since Runx2 directly regulated Fgfr2 and the knockdown of Fgfr2 was effective for inhibiting the proliferation of osteoblast progenitors, the regulation of FGFR2 by RUNX2 may also play an important role in the development and progression of some breast cancers by enhancing cell proliferation.
In conclusion, the comparison of Sp7 −/− mice, Sp7
Runx2 +/-mice, and Runx2 −/− mice revealed the requirement of Runx2 in the proliferation of osteoblast progenitors. Runx2 regulated it, at least partly, through the regulation of Fgfr2 and Fgfr3. Since Fgf signaling enhances the ability of Runx2 for transcriptional activation, the reciprocal regulation of Runx2 and Fgf signaling will play important roles in skeletal development, the pathogenesis of craniosynostosis, and the progression of some breast cancers.
Materials and Methods
Generation of transgenic and gene-targeting mice. We generated Runx2 transgenic mice under the control of the Prrx1 promoter using enhanced green fluorescent protein (EGFP)-Runx2 fusion DNA {Tg(Prrx1-EGFP-Runx2) mice}, EGFP transgenic mice under the control of the Prrx1 promoter {Tg(Prrx1-EGFP) mice}, and Runx2 −/− mice as previously described 23, 59 . In briefly, Prrx1 promoter-EGFP-Runx2 DNA fragment or Prrx1 promoter-EGFP DNA fragment was injected into the pronuclei of fertilized eggs from C57BL/6 x C3H F 1 . As Tg(Prrx1-EGFP-Runx2) mice died at birth, we analyzed the F 0 generation. The expression of transgenic embryos were screened by EGFP observation or real-time RT-PCR. Sp7 −/− mice were generated as previously described 60 .
Runx2
+/-mice were backcrossed with C57BL/6 more than ten times. Sp7 +/-mice were generated and maintained in C56BL/6 background. Prior to the study, all experiments were reviewed and approved by the Animal Care and Use Committee of Nagasaki University Graduate School of Biomedical Sciences (No. 1403111129-21). All animal experiments were performed in accordance with the law of humane treatment and management of animals in Japan, the standards for the breeding, maintenance and reducing pains of experimental animals by Ministry of the Environment in Japan, the basic guidelines of animal experiments by Ministry of Education, Culture, Sports, Science and Technology in Japan, and the rules for animal experiments in Nagasaki University.
Histological and immunohistochemical examinations. Tissues were fixed in 4% paraformaldehyde/0.1 M phosphate buffer and embedded in paraffin, and sections (thickness of 4 μm) were stained with hematoxylin and eosin (H-E). Immunohistochemical analyses were performed using a monoclonal anti-Runx2 antibody (1:200 dilution; Medical & Biological Laboratories, Nagoya, Japan) and polyclonal rabbit anti-Fgfr2 antibody (1:1000 dilution; GeneTex, Inc., Irvine, USA) as previously described 61 . Sections were counterstained with Methyl green. Immunohistochemistry without the anti-Runx2 antibody or anti-Fgfr2 antibody showed no SCieNTifiC RepoRts | (2018) 8:13551 | DOI:10.1038/s41598-018-31853-0 significant signals (data not shown). TUNEL staining was performed using the ApopTag ® system (Intergen, Burlington, MA). For analysis of BrdU incorporation, we subcutaneously injected pregnant mice with 100 μg BrdU/g body weight 1 h before sacrifice. We processed the embryos for histological analysis and detected BrdU incorporation using BrdU staining kit (Invitrogen). The sections were counterstained with hematoxylin.
In situ hybridization. In in situ hybridization, single-stranded RNA probes labeled with digoxigenin-11-UTP were prepared using a DIG RNA labeling kit (Roche, Basel Switzerland) according to the manufacturer's instructions. Sections were hybridized using mouse Fgf8 and Col1a1 antisense probes as described previously 39 . Whole mount in situ hybridization was performed using Fgf10, Fgf8, Fgf4, and Shh antisense probes as described previously 62 . The in situ hybridization of sections and whole embryos using sense probes showed no significant signals (data not shown).
Real-time RT-PCR. Real-time RT-PCR was performed using a THUNDERBIRD SYBR qPCR Mix (Toyobo) and Light Cycler 480 real-time PCR system (Roche Diagnostics). TaqMan PCR for Fgfr1, Fgfr2, Fgfr3, Runx1, Runx2, Runx3, and Sp7 was performed using a THUNDERBIRD Probe qPCR Mix (Toyobo). Primer sequences and information on TaqMan Probes are shown in Supplemental Table 6 . We normalized values to that of β-actin.
Cell culture and adenoviral transfer. Wild-type, Sp7
−/− , and Runx2 −/− osteoblast progenitors were prepared from calvariae at E18.5. The calvariae were cut into small pieces and cultured for 10-14 days in three-dimensional collagen gel (Cell matrix, Nitta Gelatin, Co., Osaka, Japan) with α-modified Minimum (α-MEM) containing 10% FBS. The cells outgrowing from the explants were retrieved by incubation for 30 min with 0.2% collagenase (Wako Pure Chemical Industries, Osaka, Japan) in PBS(−) at 37 °C. In this method, the main cell types isolated were osteoblast progenitors and osteoblasts at an early differentiation stage with low alkaline phosphatase activity and virtually no osteocalcin production 59 . Cells were plated in 24-well plates at a density of 5 × 10 4 /well in αMEM supplemented with 10% fetal bovine serum (FBS). At confluency, cells were infected with an adenovirus expressing EGFP or type II Runx2-EGFP at a multiplicity of infection of 10 for 2 hrs. The mouse pluripotent mesenchymal cell line, C3H10T1/2, was purchased from the RIKEN Cell Bank (Tsukuba, Japan), and cultured in BME supplemented with 10% FBS.
